By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



1 North Waukegan Road

North Chicago  Illinois  60064  U.S.A.
Phone: 1-800-255-5162 Fax: n/a


AbbVie (NYSE:ABBV) is a global, research-based biopharmaceutical company. AbbVie’s mission is to apply the expertise, dedication, and creativity of its people to develop and market advanced therapies that address some of the world's most complex and serious diseases. AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries.

Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products — Imbruvica®, Venclexta™, and Empliciti™ — and a pipeline containing multiple promising new molecules that are being studied in nearly 200 clinical trials in 19 different types of cancer.

AbbVie is expanding its oncology hub on the West Coast, with three sites in the San Francisco Bay Area (Redwood City, South San Francisco, and Sunnyvale) focused on the discovery and development of novel oncology therapies. More than 1,000 AbbVie scientists, clinicians, and product developers with strong entrepreneurial roots work across these three sites. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments.




CEO: Richard A. Gonzalez

CFO: William J. Chase


Please click here for Abbvie job opportunities.


Please click here for clinical trial information..


Key Statistics

Ownership: Public

Web Site: AbbVie
Symbol: ABBV

Company News
Biogen (BIIB) And AbbVie (ABBV) Receive Health Canada Approval Of Once-Monthly ZINBRYTA (Daclizumab Beta) For Multiple Sclerosis 12/9/2016 7:53:34 AM
AbbVie (ABBV) Release: Late-Breaking Ibrutinib (IMBRUVICA) Data Show Complete Or Partial Response In Two-Thirds Of Patients With Chronic Graft-Versus-Host-Disease, A Frequent And Potentially Life-Threatening Complication Of Stem Cell Transplant 12/6/2016 9:15:43 AM
AbbVie (ABBV) Release: New Phase 2 Data Show Nearly Half Of Patients With Relapsed/Refractory Marginal Zone Lymphoma (MZL) Respond To Treatment With Ibrutinib (IMBRUVICA) 12/6/2016 6:35:45 AM
AbbVie (ABBV) Release: Favorable Response Rates Suggest Promise Of Ibrutinib (IMBRUVICA) Combination Therapy In Two Common Types Of Non-Hodgkin's Lymphoma 12/5/2016 8:57:00 AM
AbbVie (ABBV) And Johns Hopkins University School of Medicine To Collaborate On Cancer Research 12/5/2016 7:25:35 AM
AbbVie (ABBV) And Northwestern University's Lurie Cancer Center To Collaborate On Multi-Year Cancer Research Agreement 12/5/2016 7:02:28 AM
AbbVie (ABBV) Release: IMBRUVICA (ibrutinib) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma 5-Year Analysis And Long-Term RESONATE-2 Follow-Up Data At American Society of Hematology 2016 Show Lasting Efficacy 12/5/2016 7:00:20 AM
AbbVie (ABBV) Receives Orphan Drug Designation For Investigational IL-23 Inhibitor Risankizumab From The U.S. FDA For The Treatment Of Pediatric Patients With Crohn's Disease 12/1/2016 10:53:04 AM
New Boston Biotech Axial Biotech Launches With $19.15 Million and Will be Helmed by AbbVie (ABBV)-GlaxoSmithKline (GSK) Vet 11/30/2016 6:06:31 AM
AbbVie (ABBV)'s Investigational, Pan-Genotypic Regimen Of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates In Chronic Hepatitis C Patients With Severe Chronic Kidney Disease 11/15/2016 8:16:28 AM